Johannes Jacobus Oosthuizen - 07 Nov 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
President, U.S. Market
Signature
/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen
Issuer symbol
MRK
Transactions as of
07 Nov 2022
Net transactions value
-$4,531,980
Form type
4
Filing time
07 Nov 2022, 15:09:20 UTC
Previous filing
01 Nov 2022
Next filing
10 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $0 +14,703 +130% $0.000000 26,047 07 Nov 2022 Direct
transaction MRK Common Stock Options Exercise $0 +17,455 +67% $0.000000 43,502 07 Nov 2022 Direct
transaction MRK Common Stock Options Exercise $0 +13,540 +31% $0.000000 57,042 07 Nov 2022 Direct
transaction MRK Common Stock Options Exercise $0 +7,045 +12% $0.000000 64,087 07 Nov 2022 Direct
transaction MRK Common Stock Sale $4,531,980 -45,561 -71% $99.47 18,526 07 Nov 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -14,703 -100% $0.000000* 0 07 Nov 2022 Common Stock 14,703 $62.07 Direct F3
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -17,455 -100% $0.000000* 0 07 Nov 2022 Common Stock 17,455 $77.62 Direct F4
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -13,540 -67% $0.000000 6,773 07 Nov 2022 Common Stock 13,540 $75.36 Direct F5
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -7,045 -33% $0.000000 14,094 07 Nov 2022 Common Stock 7,045 $73.73 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.3700 to $99.5800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2 Holdings include shares acquired in dividend reinvestment transactions.
F3 The options became exercisable in three equal installments on 5/5/2018, 5/5/2019, and 5/5/2020.
F4 The options became exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022.
F5 The options become exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
F6 The options become exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.